Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

The following table summarizes revenue by revenue source as follows:


	Three Months Ended March 31,
Major Products/Service Lines (in thousands)	2021		2020
Product revenue, net(1)	$	87,319	$	90,213
License and royalty revenues	5,190		491
Total revenues	$	92,509	$	90,704

________________________________

(1)The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the

same revenue recognition policies and judgments for all of its principal products.

The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists of AZEDRA and other oncologic therapeutics. Strategic partnerships and other includes partnerships related to other products, such as RELISTOR, that improve patient outcomes and care.

Revenue by product category on a net basis is as follows:


	Three Months Ended March 31,
(in thousands)	2021		2020(1)
DEFINITY	$	55,971	$	52,505
TechneLite	22,800		22,779
Other precision diagnostics	6,984		13,057
Total precision diagnostics	85,755		88,341
Radiopharmaceutical oncology	1,500		1,968
Strategic partnerships and other	5,254		395
Total revenues	$	92,509	$	90,704

________________________________

(1)The Company reclassified rebates and allowances of $4.7 million for the three months ended March 31, 2020 within each product category, which included $4.3 million for DEFINITY, $0.3 million for TechneLite and $0.1 million for other precision diagnostics.